Best of IGCS 2022 Annual Global Meeting-Master Session: Uterine Cancer - Management of Endometrial Cancer in The Molecular Era

Video Transcription

Video Summary

In a video, it was discussed how algorithms can analyze histopathological slides to predict molecular subtypes of endometrial cancer, reducing the need for expensive molecular testing. This method could be a cost-effective and accessible way to classify the cancer in low-resource settings. Additionally, there are efforts to develop point-of-care molecular testing devices that can rapidly and inexpensively analyze genetic mutations, providing a molecular classification and guiding treatment decisions in low-resource settings. The incorporation of molecular classification into clinical practice is still in its early stages, but promising solutions are on the horizon, enabling more personalized treatment approaches for endometrial cancer patients.<br /><br />Another part of the video focused on the Uterine Cancer Master Session at the IGCS conference, where the importance of molecular profiling in the diagnosis and treatment of endometrial cancer was emphasized. Different molecular subtypes of the cancer were discussed, along with their prognostic significance. Biomarkers, particularly DNA mismatch repair deficiency (DMMR), were highlighted as important in guiding treatment decisions, with high response rates to immunotherapy seen in DMMR endometrial cancer patients. However, more research is needed to understand the origin of DMMR tumors and its impact on treatment response. The session also addressed platinum resistance and the need for better treatment options in the advanced and recurrent setting, emphasizing the importance of using novel therapies based on molecular profiling. <br /><br />Overall, the video emphasizes the growing importance of molecular profiling in guiding personalized treatment for endometrial cancer patients. No specific credits were mentioned for the video content.

Keywords

algorithms

histopathological slides

molecular subtypes

endometrial cancer

molecular testing

low-resource settings

point-of-care devices

genetic mutations

molecular classification

treatment decisions

personalized treatment

molecular profiling

prognostic significance

biomarkers

DNA mismatch repair deficiency